|1.||Jost, Gregor: 7 articles (12/2014 - 04/2011)|
|2.||Pietsch, Hubertus: 7 articles (12/2014 - 04/2011)|
|3.||Mahnken, Andreas H: 3 articles (04/2012 - 04/2011)|
|4.||Krause, Werner: 3 articles (09/2011 - 05/2002)|
|5.||Lenhard, Diana C: 2 articles (12/2014 - 12/2011)|
|6.||Lengsfeld, Philipp: 2 articles (05/2012 - 12/2011)|
|7.||Kocabay, Gonenc: 2 articles (01/2012 - 01/2012)|
|8.||Wintersperger, Bernd J: 2 articles (01/2012 - 10/2007)|
|9.||Karabay, Can Yucel: 2 articles (01/2012 - 01/2012)|
|10.||Nikolaou, Konstantin: 2 articles (01/2012 - 10/2007)|
|1.||Renal Insufficiency (Renal Failure)
01/01/1989 - "This open study showed that after i.v. injection of a bolus of iopromide 370, a new nonionic contrast medium, there was no untoward effect on renal function in patients with renal insufficiency. "
08/01/2001 - "These findings indicate that the determination of plasma clearance of iohexol/iopromide is a simple, rapid, and accurate method that can indeed be used for estimating GFR in ICU patients with normal renal function or even different degrees of renal insufficiency."
07/15/2011 - "Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography."
01/01/1998 - "The administration of the nonionic dimeric contrast medium iodixanol, or of the nonionic monomer iopromide, entailed a low nephrotoxic potential in patients with mild to moderate renal insufficiency undergoing excretory urography."
09/01/1998 - "This double blind, comparative, randomized, parallel trial compared the efficacy of iodixanol (non-ionic dimer) and iopromide (non-ionic monomer) in 100 patients with mild to moderate renal insufficiency (serum creatinine of 135 to 265 mumol l-1) who underwent i.v. urography. "
11/01/2014 - "Greater delivery of iopromide was shown to improve the precision of the measurement of tumor pHe, but the agent did not influence the tumor pHe. "
11/01/2014 - "The ratio of the two CEST effects was used to measure pH. Routes of administration of iopromide were evaluated to ensure sufficient delivery of the agent to the tumor. "
10/01/2013 - "Dynamic contrast-enhanced CT detects early treatment effects on tumor microvasculature after a single dose of regorafenib, independently of the used CA. Gadomer showed a later optimal imaging window than iopromide did. "
05/01/2002 - "To investigate the efficacy of the new liver-specific x-ray contrast agent, Dy-EOB-DTPA, in rabbits with VX2 liver tumors by spiral computed tomography (CT) in comparison to iopromide. "
09/01/2011 - "The aim of this study was to evaluate the computed tomography (CT)-imaging potential of iopromide-carrying liposomes (SPC/CH/SPG, 6:3:1) of approximately 200 nm in diameter in healthy rabbits and in rabbits with implanted liver tumors in an intraindividual comparison with iopromide. "
05/01/1994 - "On a scale of 0 (none) to 3 (severe) for heat and pain, respectively, the mean scores were 1.08 and 0.43 for iopromide in comparison with 1.15 and 0.35 for the comparator media. "
05/01/1994 - "Excellent tolerance was noted, with no patients reporting localized pain; there were low rates of mild to moderate warmth on injection (8.5% for iopromide versus 9.5% for comparators; P > .10). "
03/01/1994 - "Iopromide produced this sensitization at doses that did not elicit evident pain reactions per se. "
07/01/1997 - "Injection-associated pain in femoral arteriography: a European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide."
06/01/2012 - "Sixty seconds after injection, associated pain and heat sensation were less frequent in iodixanol in comparison with iopromide (P = 0.03). "
09/01/2005 - "The incidence of allergic reactions was similar if ioxaglate was used alone or in combination with iopromide (p=0.478). "
09/01/2005 - "In the "planned" group, 7 of 165 patients (4.2%) receiving ioxaglate had an allergic reaction as opposed 0.0% (0 of 124 patients) in the iopromide group (p=0.021). "
09/01/2005 - "With respect to the "follow on" group, allergic reactions occurred in 9 of 150 patients (6.0%) who received the combination of ioxaglate and iopromide versus 1 of 93 (1.1%) who only received iopromide (p=0.094). "
03/01/1995 - "Iopromide caused no appreciable hemodynamic alterations associated with the changes in atrial natriuretic peptide and antidiuretic hormone and no evidence of allergy-mediated reactions in all volunteers."
03/01/1995 - "Iopromide did not induce substantial changes in the other vasoactive peptides or in allergy-mediated substances after the contrast medium was injected. "
01/01/1989 - "In spite of a bias--5 patients with iopromide 370 had myocardial infarction, versus one with ioxaglate 320--there were fewer adverse effects with iopromide 370. "
01/01/2012 - "In conclusion, in a population of unselected patients with ST-segment elevation acute myocardial infarction who underwent primary percutaneous coronary intervention, iopromide was not inferior to iodixanol in the occurrence of CI-AKI; no significant differences were found in terms of tissue-level reperfusion and major adverse cardiac events between the 2 contrast agents."
01/01/2012 - "Herein, we described a case of acute anterior myocardial infarction induced by the contrast agent iopromide (Ultravist). "
01/01/2012 - "The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty for Acute Myocardial Infarction (CONTRAST-AMI) trial is a prospective, randomized, single-blind, parallel-group, noninferiority study aiming to evaluate the effects of the low-osmolar contrast medium iopromide compared to the iso-osmolar agent iodixanol on CI-AKI and tissue-level perfusion in patients with ST-segment elevation acute myocardial infarction. "
|6.||dysprosium ethoxybenzyl DTPA
|8.||Ioxaglic Acid (Ioxaglate Meglumine)
|1.||Angioplasty (Angioplasty, Transluminal)
|5.||Homologous Transplantation (Allograft)